Smith R, Owen LA, Trem DJ, et al. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing’s sarcoma. Cancer Cell. 2006;9(5):405-16. doi:10.1016/j.ccr.2006.04.004
Miller PG, Al-Shahrour F, Hartwell KA, et al. In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell. 2013;24(1):45-58. doi:10.1016/j.ccr.2013.05.004
Watanabe H, Brooks AN, Meyerson M. Breaking down RET breakpoints in lung adenocarcinoma. J Thorac Oncol. 2014;9(5):590-2. doi:10.1097/JTO.0000000000000168
Placke T, Faber K, Nonami A, et al. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. Blood. 2014;124(1):13-23. doi:10.1182/blood-2014-02-558114
Riggi N, Knoechel B, Gillespie SM, et al. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. Cancer Cell. 2014;26(5):668-81. doi:10.1016/j.ccell.2014.10.004
Chen A, Koehler AN. Drug discovery. Tying up a transcription factor. Science. 2015;347(6223):713-4. doi:10.1126/science.aaa6119
Bandopadhayay P, Ramkissoon LA, Jain P, et al. MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nat Genet. 2016;48(3):273-82. doi:10.1038/ng.3500